Tags : Adaptimmune

Weekly Snapshot

PharmaShots Weekly Snapshot (January 13-17, 2020)

1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart 2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, […]Read More

Biotech

Astellas and Adaptimmune Signs Co-Exclusive Agreement for Universal Donor Cell

Shots: Adaptimmune to receive $50M up front, ~73.75M development milestones/ target (if product co-developed & co-commercialized by both companies) and $147.5M as milestones/product & $110M as commercial milestone if products developed by Astellas. Additionally, Adaptimmune to receive up to $7.5M/ yr. as research funding and royalties on net sales of the products Astellas to receive […]Read More